Table 4 Effect of differing assumptions on the base-case ICER
Parameter | Increase/Decrease in ICER (TB cases averted) | Increase/Decrease in ICER (TB deaths averted) |
|---|---|---|
Annual Risk of Infection (ARI) | Â | Â |
2% | + 79.86% | + 79.71% |
4% | - 39.88% | - 39.83% |
MVA85A vaccine cost (USD) | Â | Â |
20.22 | - 48.35% | - 48.35% |
48.22 | + 120.87% | + 120.87% |
MVA85A vaccine up-take | Â | Â |
76.4% | + 0.14% | + 0.12% |
89.5% | - 0.07% | - 0.06% |
MVA85A vaccine efficacy | Â | Â |
12.3% | + 69.90% | + 69.81% |
22.3% | - 38.55% | - 38.52% |
Discounting | Â | Â |
0% | -26.15% | - 27.61% |
6% | 28.14% | + 30.72% |